Despite the recent consensus on the eligibility of adjuvant systemic therapy in @entity1 with @entity0 (NNBC) based on clinicopathologic criteria, specific biological markers are needed to predict sensitivity to the different available therapeutic options. We examined the feasibility of developing a genomic predictor of chemotherapy response and recurrence risk in 185 @entity1 with NNBC using assembled arrays containing 2,460 bacterial artificial chromosome clones for scanning the genome for DNA copy number changes. After surgery, 90 @entity1 received @entity4349 -based chemotherapy, whereas 95 did not. @entity440 was administered to @entity1 with hormone receptor-positive @entity5 . The association of genomic and clinicopathologic data and outcome was computed using Cox proportional hazard models and multiple testing adjustment procedures. Analysis of NNBC genomes revealed a common genomic signature. Specific DNA copy number aberrations were associated with hormonal receptor status, but not with other clinicopathologic variables. In @entity1 treated with chemotherapy, none of the genomic changes were significantly correlated with recurrence. In @entity1 not receiving chemotherapy, deletion of eight bacterial artificial chromosome clones clustered to chromosome 11q was independently associated with relapse (disease-free survival at 10 years+/-SE, 40%+/-14% versus 86%+/-6%; P<0.0001). The 54 @entity1 with deletion of 11q (29%) did not present more aggressive clinicopathologic features than those without 11q loss. The adverse influence of 11q deletion on clinical outcome was confirmed in an independent validation series of 88 @entity1 with NNBC. Our data suggests that @entity1 with NNBC with the 11q deletion might benefit from @entity4349 -based chemotherapy despite other clinical, pathologic, or genetic features. However, these initial findings should be evaluated in randomized clinical trials.

Deletion of chromosome 11q predicts response to @entity4349 -based chemotherapy in early XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['Tamoxifen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['lymph node-negative breast cancer'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
